1. Others
  2. Androgen Receptor

Androgen Receptor

Androgen receptor (AR) is a type of nuclear receptor that is activated by binding of either of the androgenic hormones testosterone or dihydrotestosterone in the cytoplasm and then translocating into the nucleus. Upon binding the hormone ligand, the receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen responsive genes. The androgen receptor is most closely related to the progesterone receptor, and progestins in higher dosages can block the androgen receptor. The main function of the androgen receptor is as a DNA-binding transcription factor that regulates gene expression. Androgen regulated genes are critical for the development and maintenance of the male sexual phenotype. Mutations in this gene are also associated with complete androgen insensitivity (CAIS).

Androgen Receptor Related Products (38):

Cat. No. Product Name Effect Purity
  • HY-70002
    Enzalutamide Antagonist 99.71%
    Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells.
  • HY-16060
    ARN-509 Antagonist 99.23%
    ARN-509 is a potent and competitive androgen receptor (AR) antagonist, binding AR with an IC50 of 16 nM.
  • HY-14650
    DHEA Inhibitor >98.0%
    DHEA is one of the most abundant steroid hormones. DHEA mediates its action via multiple signaling pathways involving specific membrane receptors and via transformation into androgen and estrogen derivatives (e.g., androgens, estrogens, 7α and 7β DHEA, and 7α and 7β epiandrosterone derivatives) acting through their specific receptors.
  • HY-14249
    Bicalutamide Agonist 99.61%
    Bicalutamide is a non-steroidal androgen receptor inhibitor.
  • HY-15194
    ASC-J9 Inhibitor 98.06%
    ASC-J9 is an androgen receptor degradation enhancer that effectively suppresses castration resistant prostate cancer cell proliferation and invasion.
  • HY-112895
    UT-155 Antagonist
    UT-155 is a selective androgen receptor (AR) antagonist, with a Ki of 267 nM for AR-RBD.
  • HY-112256
    ACP-105 Modulator 98.37%
    ACP-105 is an orally available, selective amd potent androgen receptor modulator (SARM), with pEC50s of 9.0 and 9.3 for AR wild type and T877A mutant, respectively.
  • HY-103184
    Proxalutamide Antagonist
    GT0918 is a potent androgen receptor (AR) antagonist.
  • HY-B0022
    Flutamide Antagonist 99.01%
    Flutamide is an antiandrogen drug, with its active metablolite binding at androgen receptor with Ki values of 55 nM, and primarily used to treat prostate cancer.
  • HY-16985
    ODM-201 Antagonist
    ODM-201 is a potent androgen receptor (AR) antagonist with an IC50 of 26 nM in AR-HEK293 cells.
  • HY-B0561
    Spironolactone Antagonist
    Spironolactone is a potent antagonist of the androgen receptor.
  • HY-B1029
    Danazol Agonist 98.28%
    Danazol is a derivative of the synthetic steroid ethisterone, that suppresses the production of gonadotrophins, and has some weak androgenic effects.
  • HY-15758
    3,3'-Diindolylmethane Antagonist 98.74%
    3,3'-Diindolylmethane is a strong, pure androgen receptor (AR) antagonist.
  • HY-16079
    AZD3514 Inhibitor 98.77%
    AZD3514 is a potent and oral androgen receptor downregulator with Ki of 2.2 μM and has ability of reducing AR protein expression.
  • HY-70002A
    N-desmethyl Enzalutamide 99.14%
    N-desmethyl Enzalutamide is the active metabolite of Enzalutamide. Enzalutamide is an androgen-receptor (AR) antagonist with IC50 of 36 nM in LNCaP cells.
  • HY-14383
    RAD140 Inhibitor 99.53%
    RAD140 is a potent, orally bioavailable, nonsteroidal selective androgen receptor modulator (SARM).
  • HY-109619
    D4-abiraterone Antagonist 99.42%
    D4-abiraterone is a major metabolite of abiraterone. D4-abiraterone is an inhibitor of CYP17A1, 3b-hydroxysteroid dehydrogenase (3βHSD) and steroid-5a-reductase (SRD5A) and also an antagonist of androgen receptor.
  • HY-18102
    GLPG0492 Modulator 99.66%
    GLPG0492 is a novel selective androgen receptor modulator; exhibited anabolic activity on muscle, strongly dissociated from the androgenic activity on prostate after oral dosing.
  • HY-N0790
    Lupeol Inhibitor >98.0%
    Lupeol is a novel androgen receptor inhibitor.
  • HY-13604
    Cyproterone acetate Antagonist 99.71%
    Cyproterone acetate is an androgen receptor (AR) antagonist with IC50 of 7.1 nM, as well as a weak progesterone receptor agonist with weak pro-gestational and glucocorticoid activity.